When we hear the terms “generic” or “off-brand,” we typically think that the product would be a significantly cheaper alternative than the name brand. Well, when it comes to generic drugs, that’s not always in the case. Here are five facts plan sponsors should know:

Plans using MedImpact Direct realized a 9% reduction in specialty costs

+5,400 tons. That’s how much the DEA has collected of expired, unwanted or unused prescription medications over the past nine years through the National Prescription Drug Take Back Day program.

Avey honored for groundbreaking work that has improved countless lives, changed pharmacy benefit management

MedImpact sponsors MIT initiative to help make high-cost curative therapies more accessible

MedImpact helps reduce opioid utilization in one of America's most affected states

As Hurricane Michael — the strongest hurricane in history to hit the Florida Panhandle — continues to surge through the Southeast with damaging winds and flood-causing rains, MedImpact is committed to providing natural disaster support to our clients and members.

The U.S. Food and Drug Administration (FDA) recently approved Takhzyro (lanadelumab-flyo) as the first preventive monoclonal antibody to treat hereditary angioedema (HAE) to help prevent attacks in patients 12 years and older. HAE is a rare and potentially life-threatening genetic disease that can cause unpredictable, debilitating episodes of painful swelling in the limbs, abdomen and airway.